ABUS vs GE · P/E 5.4, rev $6.2M vs P/E 44, rev $45.85B
Arbutus Biopharma Corp (ABUS) versus GE Aerospace (GE) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
GE Aerospace (GE) is a aerospace & defense company listed on NYSE. It is led by Larry Culp.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported GE revenue for 2025-12-31 was $45.85B. Net income was $8.70B. Revenue was up 324.1% from 2024-12-31 to 2025-12-31. GE currently screens at market cap $373.04B and trailing P/E 44.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. GE currently screens at market cap $373.04B and trailing P/E 44.4.
Not investment advice. Open the ABUS and GE stock pages for the full models.
Not investment advice.